Fourth Quarter and Full Year 2025 Earnings Call F E B R U A R Y 2 3 , 2 0 2 6 ©2026 Myriad Genetics, Inc. Forward-looking statements and Non-GAAP financial measures Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management's current expectations and the actual events or results may differ materially and adv ...

Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth qu ...

Group 1 - The core viewpoint of the article highlights the frequent changes in beneficial ownership disclosures for Myriad Genetics (MYGN.US), indicating active involvement from institutional investors [1][3] Group 2 - On February 10, 2026, State Street Corporation reported acquiring a 6.4% beneficial ownership, totaling 5,966,567 shares, effective as of December 31, 2025 [2] - Glenview Capital Management disclosed holding approximately 5.30% of shares, equating to 4,941,058 shares on the same date [2] - The company submitted multiple SCHEDULE 13G regulatory filings on February 4, 9, and 12, 2026, updating the changes in shareholding [2] Group 3 - On January 12, 2026, Myriad Genetics released an 8-K report concerning operational matters, which, along with the ownership statements from February 2026, indicates heightened activity from institutional investors that may influence market sentiment [3]

Core Insights - Myriad Genetics announced the publication of the analytical validation of the FirstGene Multiple Prenatal Screen, demonstrating exceptional sensitivity and specificity for each test component [1][2] Group 1: Test Validation and Performance - The study assessed nearly 500 samples and found that every component of the FirstGene screen achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity [2] - The FirstGene screen is designed to analyze key aspects of maternal and fetal genomes simultaneously, enhancing accuracy and reproducibility [3] Group 2: Clinical Application and Utility - The FirstGene screen aims to streamline prenatal genetic risk assessment by combining aneuploidy screening, recessive screening, and fetomaternal antigen testing into a single assay [4] - The screen is currently being utilized in the CONNECTOR study, which evaluates its performance in real-world clinical practice and aims to support clinical validity and utility [5] Group 3: Technological Innovation - The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to improve genotype resolution [3] - The publication of these results is considered a significant milestone towards the broad commercialization of the FirstGene screen [3]

Core Insights - Wall Street analysts expect Myriad Genetics (MYGN) to report a quarterly loss of -$0.02 per share, reflecting a year-over-year decline of 166.7% [1] - Revenues are projected to be $207.59 million, which is a decrease of 1.4% compared to the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analysts' forecasts [1] Revenue Estimates - The consensus estimate for 'Revenue by core product - Prenatal' is $47.02 million, representing a year-over-year increase of 4.7% [3] - 'Revenue by core product - Hereditary Cancer' is expected to reach $94.87 million, suggesting a slight increase of 0.6% year over year [4] - 'Revenue by core product - Pharmacogenomics' is forecasted at $36.87 million, indicating a decline of 9.2% from the prior-year quarter [4] - 'Revenue by core product - Tumor Profiling' is estimated to be $28.59 million, reflecting a decrease of 7.2% year over year [4] Stock Performance - Over the past month, shares of Myriad have declined by 20.8%, while the Zacks S&P 500 composite has only decreased by 1.3% [5] - MYGN currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [5]

Group 1: Financial Performance - The company raised its full-year revenue guidance for 2025 to $325 million, representing a 15% year-over-year growth, and the market will focus on whether the actual performance meets or exceeds this expectation [1] Group 2: Business Development - The company is emphasizing investments in AI and digital pathology to enhance laboratory service efficiency and advance its therapeutic development pipeline. In 2026, attention will be on the commercialization progress of AI technology in genetic testing and clinical breakthroughs in its therapeutic pipeline, particularly in oncology [2] Group 3: Industry Policy and Environment - The FDA approval process is becoming more standardized in 2026, and competition in the precision medicine field, particularly at the intersection of gene editing and AI, is intensifying. The company needs to maintain its innovative edge amid technological advancements in the sequencing domain [3]

Core Insights - Myriad Genetics, Inc. will hold its fourth quarter and full year 2025 earnings conference call on February 23, 2026, at 4:30 pm ET, with earnings released after market close on the same day [1] - The company is participating in three upcoming investor healthcare conferences, including the TD Cowen 46th Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference [3][5] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic tests that assess disease risk and guide treatment decisions [4]

Core Insights - Myriad Genetics is set to transition its Precise MRD™ assay from research-use-only to a limited clinical launch in March 2026, starting with breast cancer and expanding to colorectal and renal cancers later in the year [1][2] Group 1: Product Launch and Expansion - The initial launch of Precise MRD will focus on breast cancer, with plans to include colorectal and renal cancers later in 2026, and potential expansion into ovarian and endometrial cancers in 2027 and beyond [2][10] - The company emphasizes its commitment to advancing precision oncology through the introduction of ultrasensitive MRD testing in clinical settings, aiming for improved patient outcomes [3][10] Group 2: Clinical Evidence and Study Findings - Precise MRD demonstrates high sensitivity, capable of detecting ctDNA down to one part-per-million (ppm), with interim studies indicating strong baseline detection and recurrence prediction in colorectal cancer and high sensitivity in breast cancer [3][5] - The MONITOR-Breast study showed that ctDNA dynamics can be effectively monitored during neoadjuvant therapy, with results indicating 100% baseline ctDNA detection across patients and significant associations between ctDNA levels and disease-free survival [5][6][7] - The MONSTAR-SCREEN-3 study reported a baseline sensitivity of 93% and highlighted that ctDNA clearance by day 50 of neoadjuvant therapy is linked to better pathological responses [6][7] Group 3: Technology and Methodology - Precise MRD utilizes a tumor-informed whole-genome sequencing (WGS)-based assay for personalized ctDNA detection, enabling high-resolution monitoring of cancer treatment responses [8] - The assay's ability to detect ctDNA at ultra-sensitive levels is crucial for effective risk stratification and monitoring of disease progression [7][8] Group 4: Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through advanced genetic and tumor genomic testing solutions [9]

Company Overview - Myriad Genetics is a leader in precision medicine and diagnostic testing, with over 30 years of experience in the field [4] - The company has pioneered BRCA1 testing for breast cancer and has published over 1,000 scientific publications [4] - In 2025, Myriad served over 55,000 healthcare providers and delivered more than 1.5 million test reports [4] Leadership and Vision - The company is led by President and CEO Sam Raha, who emphasizes the noble purpose of advancing health and well-being for all [3][2] - The leadership team is committed to making a significant impact in the healthcare sector [3] Current Position and Future Outlook - Myriad Genetics is at an important inflection point, indicating potential growth and strategic developments ahead [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]